NCT05425550 (PRO2) is a NA clinical trial of medidux™ app in Breast Cancer, sponsored by Palleos Healthcare GmbH.

Who is sponsoring NCT05425550?

NCT05425550 is sponsored by Palleos Healthcare GmbH.

What drugs are being tested in NCT05425550?

Interventions in NCT05425550: medidux™ app.

What condition does NCT05425550 study?

NCT05425550 studies Breast Cancer.

Is NCT05425550 still recruiting?

NCT05425550 is currently terminated. Last updated 22 September 2025.

Last reviewed 2025-09-22 · How we verify

NCT05425550: PRO2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of the Medidux™ Digital Health Application in Patients With HER2-positive Breast Cancer.

Terminated NA Last updated 22 September 2025

What this trial tests

NA trial testing medidux™ app in Breast Cancer in 196 participants. Terminated before completion.

Timeline

29 August 2022

Primary endpoint
5 June 2025

5 June 2025

Quick facts

Lead sponsor	Palleos Healthcare GmbH
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	196
Start date	29 August 2022
Primary completion	5 June 2025
Estimated completion	5 June 2025
Sites	1 location across Switzerland

Drugs / interventions tested

medidux™ app

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Palleos Healthcare GmbH — full company profile →

Who can join

18 and older, any sex, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Multicenter, prospective, randomised and controlled study to evaluate the medidux™ app during an observation period of 12 weeks (maximum 16 weeks in case of shifts in the initially planned therapy).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Digital therapeutics in the clinic.
Phan P, Mitragotri S, Zhao Z. · · 2023 · cited 39× · PMID 37476062 · DOI 10.1002/btm2.10536
Impact of Electronic Patient-Reported Outcomes on Unplanned Consultations and Hospitalizations in Patients With Cancer Undergoing Systemic Therapy: Results of a Patient-Reported Outcome Study Compared With Matched Retrospective Data.
Trojan A, Kühne C, Kiessling M, Schumacher J, et al · · 2024 · cited 3× · PMID 38710048 · DOI 10.2196/55917

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Palleos Healthcare GmbH trials

Trials by the same sponsor.

NCT04770272 — Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy · Phase 2 · terminated
NCT03272477 — Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine · Phase 2 · completed
NCT03220178 — Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine · Phase 4 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05425550 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Palleos Healthcare GmbH
Last refreshed: 22 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05425550.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing